| Zeit | Aktuelle Nachrichten Sprache: 
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.10. | Journey Medical Reports Pooled Phase 3 Data For Emrosi In Rosacea | 2 | RTTNews | ||
| 24.10. | Journey Medical's Emrosi shows superior efficacy for rosacea | 1 | Investing.com | ||
| 26.09. | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 22.09. | Summers Value Partners' Update on Journey Medical (DERM) | 5 | Insider Monkey | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 28.08. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 25.08. | H.C. Wainwright stuft Journey Medical mit "Kaufen" ein - Rosacea-Medikament Emrosi als entscheidender Faktor | 9 | Investing.com Deutsch | ||
| 25.08. | H.C. Wainwright initiates Journey Medical stock with Buy rating on Emrosi potential | 2 | Investing.com | ||
| 20.08. | Journey Medical setzt auf Rosacea-Mittel Imrozi für Profitabilitätswende | 5 | Investing.com Deutsch | ||
| 13.08. | Journey Medical targets sustained EMROSI momentum and profitability through 2025 as prescriber base nearly triples | 4 | Seeking Alpha | ||
| 12.08. | Journey Medical Corp - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 12.08. | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 12.08. | Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 534 | GlobeNewswire (Europe) | Second quarter 2025 revenues were $15.0 million  Emrosi net sales of $2.8 million generated in first full quarter on the market  The Company joined the Russell 2000® and Russell 3000® Indexes in June... ► Artikel lesen | |
| 11.08. | Examining the Future: Journey Medical's Earnings Outlook | 2 | Benzinga.com | ||
| 07.08. | Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 | 3 | GlobeNewswire (USA) | ||
| 05.08. | Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025 | 1 | GlobeNewswire (USA) | ||
| 14.07. | Journey Medical Corp - 8-K, Current Report | 3 | SEC Filings | ||
| 14.07. | Journey Medical's rosacea treatment reaches 65% commercial coverage | 2 | Investing.com | ||
| 14.07. | Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi | 2 | GlobeNewswire (USA) | ||
| 24.06. | Journey Medical to join Russell 2000 and 3000 indexes | 3 | Investing.com | ||
| 24.06. | Journey Medical Corporation: Journey Medical to Join Russell 2000 and Russell 3000 Indexes | 1 | GlobeNewswire (USA) | 
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,325 | +1,48 % | Pharmariesen im Wettlauf: Novo Nordisk kontert Pfizer: Aktie des Übernahmekandidaten steigt zweistellig! | © Foto: Jonathan Raa - Sipa USANovo Nordisk greift nach Metsera und bietet neun Milliarden US-Dollar. Das Pharmaunternehmen kontert Pfizer im Rennen um die Zukunft des Gewichtsmanagements.Der dänische... ► Artikel lesen | |
| GILEAD SCIENCES | 105,02 | +6,04 % | Chance für Anleger?: Gilead gibt Zahlen bekannt - Boost für Gewinnprognose? | Gilead gab steigende Umsätze mit HIV-Medikamentenverkäufen bekannt. Das Unternehmen erwartet in Zukunft Großes.Das Unternehmen meldete am Donnerstag einen Anstieg der HIV-Medikamentenverkäufe um 4 Prozent... ► Artikel lesen | |
| ELI LILLY | 737,40 | +1,29 % | Eli Lilly revolutioniert den Abnehmmarkt: Milliarden Dosen der neuen GLP-1-Pille Orforglipron bereit | Der US-Pharmariese Eli Lilly bereitet sich auf die weltweite Markteinführung seiner Abnehmpille Orforglipron vor. Mit Milliarden bereits produzierter Dosen und einem Rekordetat für Forschung und Entwicklung... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 367,15 | +2,90 % | H.C. Wainwright Reiterates a Buy Rating on Vertex Pharmaceuticals (VRTX) | ||
| EYEPOINT PHARMACEUTICALS | 10,465 | -0,85 % | EyePoint Pharmaceuticals, Inc.: EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 | ||
| ASTRIA THERAPEUTICS | 10,800 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| OPKO HEALTH | 1,246 | -0,61 % | OPKO Health, Inc.: OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results | MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 164,00 | +1,23 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 118,90 | +0,85 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025 | DUBLIN, Oct. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5... ► Artikel lesen | |
| UNITED THERAPEUTICS | 388,50 | -0,94 % | United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark | ||
| ROYALTY PHARMA | 32,220 | +0,81 % | What Do Analysts Think About Royalty Pharma Plc (RPRX)? | ||
| CATALYST PHARMACEUTICALS | 18,430 | +1,60 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Lupin Pharmaceuticals | CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 54,98 | +0,26 % | AKTIONÄR-Tipp BridgeBio erneut mit Kurssprung - Aktie bereits 100 Prozent im Plus | Bei der Aktie des US-Biotech-Unternehmens BridgeBio geht es weiter steil aufwärts. Bereits in den vergangenen Monaten hatte sich das Papier nach der Empfehlung als Jahrestipp in Ausgabe 52/2024 - 01/2025... ► Artikel lesen | |
| TG THERAPEUTICS | 31,540 | +7,22 % | TG Therapeutics, Inc.: TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI | NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated... ► Artikel lesen | |
| AVADEL PHARMACEUTICALS | 16,200 | -0,61 % | Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc | DJ Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
The Vanguard Group, Inc. (IRSH) 
Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc 
24-Oct-2025 / 14:31 GMT/BST 
... ► Artikel lesen |